Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis

Trial Profile

An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety and Sustained Efficacy of Denosumab (AMG162) in the Treatment of Postmenopausal Osteoporosis

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jun 2019

At a glance

  • Drugs Denosumab (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions
  • Acronyms FREEDOM extension
  • Sponsors Amgen
  • Most Recent Events

    • 24 May 2019 Results of non-vertebral facture risk reduction upto 10 years by using data from this study and its extension study published in the Journal of Clinical Endocrinology and Metabolism.
    • 13 Feb 2019 Results assessing the rate of osteonecrosis of the jaw (ONJ) were published in the Journal of Clinical Endocrinology and Metabolism
    • 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top